Skip to main content
. 2017 Jun 7;12(6):e0168702. doi: 10.1371/journal.pone.0168702

Fig 2. Gametocyte prevalence during 42-day follow-up.

Fig 2

Gametocyte prevalence for each regimen, as measured by microscopy. Dihydroartemisinin-piperaquine (DHP) was dosed on days 0–2. Primaquine (PQ) was dosed on day 2. Error bars indicate the upper and lower limits of the 95% CI. *Indicates a statistically significant difference between groups based on a one-tailed Fisher’s exact test.